BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29913253)

  • 1. C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy.
    Wang Y; Rapalino O; Heidari P; Loeffler J; Shih HA; Oh K; Mahmood U
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1024-1028. PubMed ID: 29913253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final Results of the Prospective Biomarker Trial PETra: [
    Seidlitz A; Beuthien-Baumann B; Löck S; Jentsch C; Platzek I; Zöphel K; Linge A; Kotzerke J; Petr J; van den Hoff J; Steinbach J; Krex D; Schmitz-Schackert G; Falk M; Baumann M; Krause M
    Clin Cancer Res; 2021 Mar; 27(5):1351-1360. PubMed ID: 33376095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
    Zhang H; Liu N; Gao S; Hu X; Zhao W; Tao R; Chen Z; Zheng J; Sun X; Xu L; Li W; Yu J; Yuan S
    J Nucl Med; 2016 Apr; 57(4):524-9. PubMed ID: 26514171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of intraoperative perfusion-weighted MRI and 5-aminolevulinic acid in relation to contrast-enhanced intraoperative MRI and
    Pala A; Reske SN; Eberhardt N; Scheuerle A; König R; Schmitz B; Beer AJ; Wirtz CR; Coburger J
    Neurosurg Rev; 2019 Jun; 42(2):471-479. PubMed ID: 29808321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study.
    Miwa K; Shinoda J; Yano H; Okumura A; Iwama T; Nakashima T; Sakai N
    J Neurol Neurosurg Psychiatry; 2004 Oct; 75(10):1457-62. PubMed ID: 15377696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
    Bosnyák E; Michelhaugh SK; Klinger NV; Kamson DO; Barger GR; Mittal S; Juhász C
    Clin Nucl Med; 2017 May; 42(5):341-347. PubMed ID: 28195901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.
    Matsuo M; Miwa K; Tanaka O; Shinoda J; Nishibori H; Tsuge Y; Yano H; Iwama T; Hayashi S; Hoshi H; Yamada J; Kanematsu M; Aoyama H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):83-9. PubMed ID: 21095072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
    Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
    Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.
    Brahm CG; den Hollander MW; Enting RH; de Groot JC; Solouki AM; den Dunnen WFA; Heesters MAAM; Wagemakers M; Verheul HMW; de Vries EGE; Pruim J; Walenkamp AME
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2404-2412. PubMed ID: 30032322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-Fluoroethyl-l-Thyrosine Positron Emission Tomography to Delineate Tumor Residuals After Glioblastoma Resection: A Comparison with Standard Postoperative Magnetic Resonance Imaging.
    Buchmann N; Kläsner B; Gempt J; Bauer JS; Pyka T; Delbridge C; Meyer B; Krause BJ; Ringel F
    World Neurosurg; 2016 May; 89():420-6. PubMed ID: 26893043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
    Ellingson BM; Abrey LE; Nelson SJ; Kaufmann TJ; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Butowski N; Ligon KL; Gerstner ER; Colman H; de Groot J; Chang S; Mellinghoff I; Young RJ; Alexander BM; Colen R; Taylor JW; Arrillaga-Romany I; Mehta A; Huang RY; Pope WB; Reardon D; Batchelor T; Prados M; Galanis E; Wen PY; Cloughesy TF
    Neuro Oncol; 2018 Aug; 20(9):1240-1250. PubMed ID: 29660006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell Lymphoma using (11)C-methionine and (18)F-FDG PET.
    Okada Y; Nihashi T; Fujii M; Kato K; Okochi Y; Ando Y; Yamashita M; Maesawa S; Takebayashi S; Wakabayashi T; Naganawa S
    Clin Nucl Med; 2012 Sep; 37(9):843-9. PubMed ID: 22889772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. l-[METHYL-(11)C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy.
    Mahasittiwat P; Mizoe JE; Hasegawa A; Ishikawa H; Yoshikawa K; Mizuno H; Yanagi T; Takagi R; Pattaranutaporn P; Tsujii H
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):515-22. PubMed ID: 17900820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.
    Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z
    Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resection of positive tissue on methionine-PET is associated with improved survival in glioblastomas.
    Ohmura K; Daimon T; Ikegame Y; Yano H; Yokoyama K; Kumagai M; Shinoda J; Iwama T
    Brain Behav; 2023 Dec; 13(12):e3291. PubMed ID: 37846176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics for residual tumour detection and prognosis in newly diagnosed glioblastoma based on postoperative [
    Shahzadi I; Seidlitz A; Beuthien-Baumann B; Zwanenburg A; Platzek I; Kotzerke J; Baumann M; Krause M; Troost EGC; Löck S
    Sci Rep; 2024 Feb; 14(1):4576. PubMed ID: 38403632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.
    Grosu AL; Weber WA; Riedel E; Jeremic B; Nieder C; Franz M; Gumprecht H; Jaeger R; Schwaiger M; Molls M
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):64-74. PubMed ID: 16111573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma.
    Chakhoyan A; Woodworth DC; Harris RJ; Lai A; Nghiemphu PL; Liau LM; Pope WB; Cloughesy TF; Ellingson BM
    J Neurooncol; 2018 Sep; 139(3):651-659. PubMed ID: 29855771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.
    Bolcaen J; Acou M; Boterberg T; Vanhove C; De Vos F; Van den Broecke C; Van Holen R; Deblaere K; Goethals I
    Nucl Med Commun; 2017 Mar; 38(3):242-249. PubMed ID: 27984537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.